Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis

Journal of Clinical Rheumatology

Volumn 20, Issue 2, 2014, Pages 68-73

  Kwon, Minkyung ^a,b   Sung, Mindong ^a   Kwon, Yong Jin ^a   Song, Young Goo ^a   Lee, Sang Won ^a   Park, Min Chan ^a   Park, Yong Beom ^a   Lee, Soo Kon ^a   Song, Jason Jungsik ^a  

^a Yonsei University College of Medicine   (South Korea)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

anti TNF therapy; chemoprophylaxis; latent tuberculosis infection; Mycobacterium tuberculosis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ACTIVE TUBERCULOSIS RISK; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; INCIDENCE; INFECTION RISK; INFLAMMATORY DISEASE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING; SEX RATIO; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; INCIDENCE; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; REGRESSION ANALYSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896709253     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000074     Document Type: Article

References (27)

1. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986-1992.
2. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antiYtumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368-2376.
3. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;1185-1206.
4. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-1265.
5. Gardam MA, Keystone EC, Menzies R, et al. AntiYtumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-155.
6. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766-1772.
7. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis care Res (Hoboken). 2012;64:625-639.
8. Joint Committee for the Development of Korean Guideline for Tuberculosis. Korean Guidelines for Tuberculosis [Korea Centers for Disease Control and Prevention Web site]. 1st ed. 2011. Available at: http://tbfree.cdc.go.kr/ tbfree/guide.do?page=11&id=4110. Accessed September, 2013.
9. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49:1-51.
10. Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start antiYTNF-alpha treatment. 2005; 800-805.
11. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3:847-850.
12. Currie GP, Emmanuel FXS, Ford D, et al. Reactivation of tuberculosis after apparently adequate chemoprophylaxis. J Infect. 2005;51:e305-308.
13. Jauregui-Amezaga A, Turon F, Ordás I, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. Journal of Crohn colitis. 2013;7:208-212.
14. Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med. 2007;4:e120.
15. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology;. Nat Rev Rheumatol. 2012;8:430-436.
16. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology. 2005;44:714-720.
17. von Kempis J, Dudler J, Hasler P, et al. Use of abatacept in rheumatoid arthritis. Swiss Med Wkly. 2012;142:w13581.
18. Greenwald MW, Shergy WJ, Kaine JL, et al. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum. 2011;63:622-632.
19. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an antiYIL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68:1580-1584.
20. World Health Organization. Global Tuberculosis Control 2011: WHO Report 2011 [World Health Organization Web site]. Available at: http://whqlibdoc.who. int/publications/2011/9789241564380-eng.pdf. Accessed August 2012.
21. Seong S-S, Choi C-B, Woo J-H, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34:706-711.
22. Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006;10:1127-1132.
23. Kim E-M, Uhm W-S, Bae S-C, et al. Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol. 2011;38:2218-2223.
24. Kim EY, Lim JE, Jung JY, et al. Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis. 2009;9:207.
25. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995;2:561-572.
26. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol. 2010;161:1-9.
27. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology. 2010;15:603-622.